Search Results

DAREON™-7: DLL3 for Advanced Neuroendocrine Cancers << Back DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT06132113 DRUG/TREATMENT : BI 764532, Carboplatin, Etoposide, Cisplatin PHASE : 1 STATUS : Recruiting SPONSOR : Boehringer Ingelheim https://www.youtube.com/watch?v=tSN7eS8fJPw DESCRIPTION: This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has 2 parts. Part A of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC. Participants get different doses of BI 764532 as an infusion into a vein. In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it. Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Boehringer Ingelheim EMAIL: clintriage.rdg@boehringer-ingelheim.com PHONE: 1-800-243-0127 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. OTHER HELPFUL RESOURCES:

<< Go back to the Podcast page EPISODE 5: TREATMENT FOR NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE What are the current treatment options for NETs? How do I know what treatments I should be on? In our fifth episode, NET expert and Medical Oncologist Dr. Randy Hecht of UCLA Health answers ten common questions about current NET treatment options (including lanreotide, octreotide, everolimus, and PRRT), as well as future treatment options. MEET DR. RANDY HECHT Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. TOP 10 GI QUESTIONS 1. Do all NET patients need to be on lanreotide or octreotide? What’s the difference between lanreotide and octreotide? 2. How do I know what treatments I should be on? 3. My doctor has recommended I take everolimus (afinitor) or CAPTEM. What is the difference and how would I make a decision? 4. My doctor has recommended I take everolimus (afinitor) or PRRT. How would I make that decision? 5. Once I have had PRRT, what would I do next if the tumor progresses? 6. How would I find out what new treatments are on the horizon for NET? 7. Would there be any treatments that negate future choices of treatment options or clinical trials? 8. What does it mean if I have bone mets? (Is my prognosis worse? Does it mean my tumors are getting worse?) 9. If you do not have Somatostatin receptors, should you still have the Gallium DOTATATE scan and if not, what tests/scans do you recommend? 10. Which treatment or other development in this field are you most excited about? What hope might you offer to those living with NET or their loved ones? DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANKS TO OUR SPONSORS

SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) << Back SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) IDENTIFIER ( ClinicalTrials.gov ) : NCT06889493 DRUG/TREATMENT : Nivolumab and Ipilimumab PHASE : 1 STATUS : Recruiting SPONSOR : Aman Chauhan, MD https://www.youtube.com/watch?v=dQ-xBFvXK1E Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors. Click here to download this transcript >>> DESCRIPTION: The purpose of this study is to determine: The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. The highest frequency of dosing of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. The highest dose and frequency of dosing of the trial intervention that targets neuroendocrine tumors with at least the same degree of effectiveness and tolerability as currently available (standard of care) treatments for patients with neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. STUDY CONTACT Name: Peter Hosein, MD Phone Number: 1 (305) 243-3462 Email: PHosein@med.miami.edu STUDY CONTACT BACKUP Name: Nailet Real Bestard, MS Phone Number: 1 (305) 243-8173 Email: nxr518@med.miami.edu

Join NCF for Dec2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=cmKEuKfOcGw Download the presentation slides >>> ABOUT Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, Medical Oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for neuroendocrine cancer. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. ABOUT DR. AMAN CHAUHAN Aman Chauhan, MD Medical Oncologist University of Miami Sylvester Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. TAKE ACTION VOICE epNEC Patient Survey November, 2025 People living with neuroendocrine carcinoma (epNEC) are invited to share their experiences through an online research survey. Patient insights will help inform future care, resources, and support for the neuroendocrine cancer community. If you are interested, click the link below (or scan the QR code) to enter your email address. You will receive a brief eligibility questionnaire and additional study details. If eligible, you will be invited to complete the full survey. Sign up here: https://s-hab.medefield.com/wix/p189895130943.aspx Survey invitations will be sent from invite@decipherinc.com within 2–3 days. Please check your spam or junk folder if needed. Your email will be used only to send the survey invitation and will be deleted after the study concludes. Thank you for considering taking part in this important study. WATCH https://www.youtube.com/watch?list=PLPAgUIq-85n_8IEEakNm9m3Gavmzrq6B5&v=_EEdMQLui4U EXPLORE High Grade Resources including videos, podcasts, articles and more For more on Clinical Trials and for the Ancora.ai Clinical Trial Finder, explore our Clinical Trials Guide T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET Download a Transcript of this Episode >> ABOUT THIS EPISODE NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. MEET SINA TESKEY, RD, CD Sina Teskey, RD, CD received her B.S. from the University of Wisconsin-Madison in 2006 and completed her dietetic internship at the University of Minnesota Medical College-Fairview in 2007. She has spent most of her career working with cancer and eating disorder patients. Sina practiced in the Twin Cities area for 10 years where she also spent time guest starring on a local TV show called Twin Cities Live to share nutrition advice. She moved to Milwaukee and has worked at Froedtert Hospital and the Medical College of Wisconsin since 2018. Sina sees all patients with cancer but specializes in GI cancers and neuroendocrine tumor patients. When she’s not working, Sina is a mom to three kids and a Labrador retriever. She loves to cook and bring people together with food. Her youngest son was diagnosed with Non-Hodgkin’s Lymphoma in 2019. His cancer journey gave insight into what having cancer means to a family and has impacted her practice profoundly. Her son Milo is now 7 years old and in remission. TOP TEN QUESTIONS Is there a diet NET patients should follow? Are there foods NET patients should avoid? Some people say there are certain “trigger foods” to avoid. What CAN I eat? What diet is helpful after bowel surgery? What about pancreas surgery? Are there vitamins or supplements recommended for NET patients? What can NET patients do about diarrhea? What diet or medications might help? What can NET patients do if they struggle with a poor appetite? What can NET patients do if they are struggling to keep on or gain weight? What can NET patients do to stay hydrated? What are pancreatic enzymes and how are they taken? Who are they recommended for? What proteins can people take if they are vegetarian or vegan given soy may be a trigger for carcinoid syndrome? What do you think of alternative diets such as the keto diet or other “special diets?” Does sugar feed cancer? What about intermittent fasting? RESOURCES READ LACNETS Nutrition Resources MAKE Energy Bites DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET << Back STELLAR-311: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT06943755 DRUG/TREATMENT : Zanzalintinib and Everolimus PHASE : 2/3 STATUS : Recruiting SPONSOR : Exelixis https://www.youtube.com/watch?v=sTWl5FZwG6k DESCRIPTION: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to STELLAR-311 Clinical Trial (Exelixis) and/or ClinicalTrials.gov to view this trial here. CONTACT: Exelixis Clinical Trials, STELLAR-311 Clinical Trial (Exelixis) EMAIL: druginfo@exelixis.com PHONE: 1-888-EXELIXIS (888-393-5494) This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. OTHER HELPFUL RESOURCES: This Exelixis study site STELLAR-311 Clinical Trial (Exelixis) includes a toll-free medical information hotline, information on the study and eligibility criteria and study sites *Please note, Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.

<< Back Gastrointestinal (GI) NETs PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) COMPOSE (GEP-NETS) NETTER-P: Lutathera in Adolescent Patients NET RETREAT of Lu-177 Retreatment vs Everolimus in Midgut NET Oral Treatment CDK4/6 Abemaciclib SSA Treatments BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors Paltusotine in Carcinoid Syndrome SORENTO™: Subcutaneous Octreotide for GEP-NETs Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas CHM-2101 CAR-T cell for GI Cancers IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Join NCF for May2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=oSqUgq6QdnM Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. ABOUT DR. AMAN CHAUHAN Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

<< Back Carcinoid Syndrome CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine in Carcinoid Syndrome

<< Back Somatostatin Analogue (SSA) CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine in Carcinoid Syndrome SORENTO™: Subcutaneous Octreotide for GEP-NETs LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma

Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC << Back Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC CLINICALTRIALS.GOV IDENTIFIER: NCT03647163 Drug/Treatment: VSV-IFNβ-NIS and Pembrolizumab PHASE: I/II STATUS: Recruiting Sponsor: Vyriad, Inc. Collaborator: Mayo Clinic https://www.youtube.com/watch?v=Pw8oSIOt0og Dr. Heloisa Soares Discusses Systemic VSV-IFNβ-NIS and Pembrolizumab DESCRIPTION: Vyriad is sponsoring the safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious. Thus, this study will test a second VSV-IFNβ-NIS dose level, 1.0x1011 TCID50. A safety assessment will be carried out after 3 patients are enrolled. If this dose schedule is well tolerated and virus PK are not negatively impacted, both the NSCLC and NEC expansion cohorts will open using this dose schedule. If 2 of the first 3 patients or 2 of the first 6 patients experience a DLT, the dose will be de-escalated to 5 x 1010. The safety run-in/dose escalation portion of this study is expected to require a minimum of 3 patients and a maximum of 18 patients (6 patients per dose level). The expansion portion of this study is expected to require a minimum of 10 per cohort. The NSCLC and NEC patients enrolled at the identified optimal dose in the dose escalation cohort would be included in the dose expansion cohort if they are evaluable for the primary endpoint in the expansion portion (4 dose escalation patients at the optimal dose are expected to roll over to the expansion). Therefore, the overall sample size details will be a maximum of 40 patients. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Jennifer Boughton EMAIL: JBoughton@vyriad.com PHONE: 908-553-3135 Shruthi Naik, PhD EMAIL: snaik@vyriad.com PRINCIPAL INVESTIGATOR: Julian R. Molina, MD, PhD Mayo Clinic

<< Go back to the Podcast page EPISODE 17: KEY CONSIDERATIONS FOR NET SURGERY Download a Transcript of this Episode >> ABOUT THIS EPISODE How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. MEET DR. ALEXANDRA GANGI Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. TOP 10 QUESTIONS 1. How do you decide if the tumors can and should be cut out? How does tumor location, tumor size, and amount of tumors factor into your decision? 2. How do you decide if someone should have a laparoscopic surgery versus open surgery? What about robotic surgery? 3. How do you decide whether or not to remove the ileocecal valve? 4. What work up should NET patients have before surgery? Should all NET patients have an echo? 5. What is the risk of carcinoid crisis with a dental procedure, a biopsy, or with surgery? How do you manage this? 6. Should NET patients be on somatostatin analogs before surgery? What about after surgery? If so, when would you restart it? 7. When would you want someone on chemotherapy or PRRT to shrink a tumor before surgery? When might you want to do surgery first followed by another treatment? 8. When would you recommend imaging after NET surgery? What type of imaging would you order? 9. Why are there differing opinions from NET specialists, specifically about surgery and what treatment should be offered as the next option? 10. What questions would you recommend NET patients ask at their surgical consultation? RESOURCES READ LACNETS Resources on Surgery Blog Practical Tips for Patients Preparing for Surgery NET VITALS NET Intro WATCH https://www.youtube.com/watch?v=dMzftWG0YpU "Surgery for NETs" - Alexandra Gangi, MD, Cedars-Sinai - 2020 LACNETS Virtual NET Conference (June 23, 2020) https://www.youtube.com/watch?v=01twnQyDEV4 "To Cut or Not to Cut? What Your NET Surgeon Wants You To Know" - Callisia Clarke, Medical College of Wisconsin - 2021 LACNETS Virtual NET Conference (June 19, 2021) https://www.youtube.com/watch?v=-38gePJDans "NET Surgery: Making Decisions & Preparing for Surgery" - Callisia Clarke, MD, Medical College of Wisconsin - 2022 LACNETS Virtual NET Conference (June 18, 2022) https://www.youtube.com/watch?v=VkgoByozjX0 "Your Pathologist & Your Pathology Report" - Sue Chang, MD, City of Hope (March 27, 2020) https://www.youtube.com/watch?v=aGp0YuHt_sU "Pathology" - Alberto Marchevsky, MD, Director of Pathology, Cedars-Sinai - 2019 LACNETS Conference (June 8, 2019) LISTEN The LACNETS Podcast Episode 3: Surgery for NETs >> The LACNETS Podcast Episode 11: Pathology for NETs >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS